Rapport Therapeutics, Inc. Operating Expenses
Rapport Therapeutics, Inc. (RAPP) reported Operating Expenses of $60.81 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:OperatingExpenses · last filed 2026-08-05
- Rapport Therapeutics, Inc. operating expenses for the quarter ending 2026-06-30 was $60.81M, a 106.15% increase year-over-year.
- Rapport Therapeutics, Inc. operating expenses for the quarter ending 2026-03-31 was $44.22M, a 63.11% increase year-over-year.
- Rapport Therapeutics, Inc. operating expenses for the quarter ending 2025-12-31 was $38.51M, a 63.72% increase year-over-year.
- Rapport Therapeutics, Inc. operating expenses for the quarter ending 2025-09-30 was $29.99M, a 38.57% increase year-over-year.
- Rapport Therapeutics, Inc. operating expenses for fiscal 2025 was $125.10M, a 50.62% increase from fiscal 2024.
- Rapport Therapeutics, Inc. operating expenses for fiscal 2024 was $83.06M, a 129.57% increase from fiscal 2023.
- Rapport Therapeutics, Inc. operating expenses for fiscal 2023 was $36.18M.
| Period end | Operating Expenses 3 month | Operating Expenses 6 month | Operating Expenses 9 month | Operating Expenses 12 month |
|---|---|---|---|---|
| 2026-06-30 | $60.81M 10-Q · filed 2026-08-05 | $105.02M 10-Q · filed 2026-08-05 | $143.53M derived: sum of 3 quarters · filed 2026-08-05 | $173.52M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $44.22M 10-Q · filed 2026-05-07 | $82.72M derived: sum of 2 quarters · filed 2026-05-07 | $112.71M derived: sum of 3 quarters · filed 2026-05-07 | $142.21M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $38.51M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $68.50M derived: sum of 2 quarters · filed 2026-03-10 | $97.99M derived: sum of 3 quarters · filed 2026-08-05 | $125.10M 10-K · filed 2026-03-10 |
| 2025-09-30 | $29.99M 10-Q · filed 2025-11-06 | $59.48M derived: sum of 2 quarters · filed 2026-08-05 | $86.59M 10-Q · filed 2025-11-06 | $110.11M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $29.50M 10-Q · filed 2026-08-05 | $56.60M 10-Q · filed 2026-08-05 | $80.13M derived: sum of 3 quarters · filed 2026-08-05 | $101.77M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $27.11M 10-Q · filed 2026-05-07 | $50.63M derived: sum of 2 quarters · filed 2026-05-07 | $72.27M derived: sum of 3 quarters · filed 2026-05-07 | $93.07M derived: sum of 4 quarters · filed 2026-05-07 |
| 2024-12-31 | $23.52M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-10 | $45.16M derived: sum of 2 quarters · filed 2026-03-10 | $65.96M derived: sum of 3 quarters · filed 2026-03-10 | $83.06M 10-K · filed 2026-03-10 |
| 2024-09-30 | $21.64M 10-Q · filed 2025-11-06 | $42.44M derived: sum of 2 quarters · filed 2025-11-06 | $59.53M 10-Q · filed 2025-11-06 | $74.33M derived: sum of 4 quarters · filed 2025-11-06 |
| 2024-06-30 | $20.80M 10-Q · filed 2025-08-07 | $37.89M 10-Q · filed 2025-08-07 | $52.69M derived: sum of 3 quarters · filed 2025-08-07 | $62.25M derived: sum of 4 quarters · filed 2025-08-07 |
| 2024-03-31 | $17.09M 10-Q · filed 2025-05-08 | $31.89M derived: sum of 2 quarters · filed 2025-05-08 | $41.45M derived: sum of 3 quarters · filed 2025-05-08 | $48.08M derived: sum of 4 quarters · filed 2025-05-08 |
| 2023-12-31 | $14.79M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-11 | $24.36M derived: sum of 2 quarters · filed 2025-03-11 | $30.99M derived: sum of 3 quarters · filed 2025-03-11 | $36.18M 10-K · filed 2025-03-11 |
| 2023-09-30 | $9.56M 10-Q · filed 2024-11-07 | $16.19M derived: sum of 2 quarters · filed 2024-11-07 | $21.39M 10-Q · filed 2024-11-07 | |
| 2023-06-30 | $6.63M 10-Q · filed 2024-08-08 | $11.82M 10-Q · filed 2024-08-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Eton Pharmaceuticals, Inc. (ETON) | United States | $1.701B | 80.74 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Xencor Inc (XNCR) | United States | $1.776B | -7.33 |
| Septerna, Inc. (SEPN) | United States | $1.783B | -63.01 |